INVENTIVA S.A.(PROM.)-,01

Inventiva appointed Axel‑Sven Malkomes as CFO, Susan Coles as chief legal officer and Pamela Herbster as chief people officer to bolster management ahead of the expected topline data from the phase‑3 NATiV3 study. The study is evaluating lanifibranor for the treatment of MASH; results are expected in Q4 2026. Jean Volatier is moving to the role of EVP finance & corporate social responsibility, and Nathalie Harroy will remain in a continuing role. » Mere på de.investing.com

Inventiva's share in Paris jumped by up to 11% after Leerink initiated coverage of the American Depositary Receipts with an "Outperform" rating. Analyst Thomas Smith described the company as "convincingly valued" and sees Inventiva as an opportunity in the growing MASH market. Leerink estimates the market potential for MASH at around $24 billion by 2035. Results from late‑phase studies of lanifibranor are expected in the second half of 2026. » Mere på de.investing.com

Inventiva has resumed trading of its ordinary shares on Euronext Paris after a temporary suspension due to a public offering of American Depositary Shares (each ADS = 1 new ordinary share). In connection with the US offering, the company raised about $150 million by selling 38.96 million ADS at $3.85 each. Inventiva continues development of lanifibranor in the approval‑relevant phase‑3 trial NATiV3; analysts confirm or raise their assessments (Piper Sandler overweight, price target $26; H.C. Wainwright target $24; Stifel buy, target $17). According to InvestingPro, despite a current ratio of 2.96, rapid cash burn remains a challenge. » Mere på de.investing.com